Snibe Diagnostic Displays Analyzers at MEDLAB Europe 2018
|
By LabMedica International staff writers Posted on 04 Oct 2018 |

Image: Snibe showcased its latest range of chemiluminescent immunoassay analyzers at MEDLAB Europe 2018 (Photo courtesy of Snibe).
Shenzhen New Industries Biomedical Engineering Co., Ltd. {(Snibe Co. Ltd.) Shenzhen, China} showcased its latest range of chemiluminescent immunoassay analyzers at MEDLAB Europe 2018 held in Barcelona, Spain, from October 2-4, 2018.
More than 150 exhibitors showcased the latest cutting edge technologies and recent developments in the medical laboratory industry at the second edition of the show. MEDLAB Europe 2018 welcomed more than 2,600 international visitors and delegates, offering international manufacturers a chance to network with over 1,000 medical dealers and distributors from Spain, Italy, France, Germany, Portugal and other countries.
Snibe is a bio-medical company specialized in clinical laboratory instruments and in vitro diagnostic reagents. The company manufactures a range of chemiluminescent immunoassay analyzers and clinical chemistry analyzers. It has achieved several milestones, such as developing China's first automated CLIA analyzer and dedicated kits in 2008 and launching the country’s first integrated system in 2012. Snibe is also the first CLIA manufacturer in China to receive FDA clearance in 2017.
Snibe offers chemiluminescent immunoassay analyzers under the MAGLUMI series and its clinical chemistry analyzers under the Biossays series. Currently, more than 3,000 hospitals in China are using the company’s MAGLUMI CLIA system. Snibe also offers the Biolumi 8000 Integrated Lab System that combines an electrolyte module, chemistry module and immunoassay module in a single platform.
More than 150 exhibitors showcased the latest cutting edge technologies and recent developments in the medical laboratory industry at the second edition of the show. MEDLAB Europe 2018 welcomed more than 2,600 international visitors and delegates, offering international manufacturers a chance to network with over 1,000 medical dealers and distributors from Spain, Italy, France, Germany, Portugal and other countries.
Snibe is a bio-medical company specialized in clinical laboratory instruments and in vitro diagnostic reagents. The company manufactures a range of chemiluminescent immunoassay analyzers and clinical chemistry analyzers. It has achieved several milestones, such as developing China's first automated CLIA analyzer and dedicated kits in 2008 and launching the country’s first integrated system in 2012. Snibe is also the first CLIA manufacturer in China to receive FDA clearance in 2017.
Snibe offers chemiluminescent immunoassay analyzers under the MAGLUMI series and its clinical chemistry analyzers under the Biossays series. Currently, more than 3,000 hospitals in China are using the company’s MAGLUMI CLIA system. Snibe also offers the Biolumi 8000 Integrated Lab System that combines an electrolyte module, chemistry module and immunoassay module in a single platform.
Latest MEDLAB 2018 News
- MEDLAB Europe 2018 Presents Latest Technologies and Developments
- MedLab Middle East Continues as World's Largest Attended Laboratory Exhibition and Conference
- Fujifilm Showcases DRI-CHEM NX700 Dry Chemistry Analyzer
- Zeesan Biotech Displays DNA Automated Extraction System
- Priorclave Highlights Its Smallest Steam Sterilizer
- HORIBA Medical Launches HELO and Yumizen G Range
- Astell Scientific Showcases Latest Autoclave Range
- AXA Diagnostics Highlights SkyLAB752 System
- Block Scientific Showcases Medical Lab Equipment Devices
- BIOBASE Displays Range Of Laboratory & Medical Analyzers
- EKF Diagnostics Showcases Latest Data Management Solutions
- Siemens Healthineers Showcases Advanced Diagnostics Analyzers
Channels
Clinical Chemistry
view channel
Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read moreMolecular Diagnostics
view channel
Novel Liquid Biopsy Technology to Advance Cancer Diagnostics
Liquid biopsies are increasingly replacing tissue biopsies in cancer care, offering a faster, minimally invasive way to assess tumor genetics from blood samples. However, current liquid biopsy methods... Read more
POC Oral Fluid Test Diagnoses HIV Infection in 20 Minutes
Timely and accurate HIV diagnosis remains a major challenge in many parts of the world, particularly in resource-constrained settings where laboratory infrastructure and trained personnel are limited.... Read moreHematology
view channel
AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
Alpha thalassemia affects millions of people worldwide and is especially common in regions such as Southeast Asia, where carrier rates can reach extremely high levels. While the condition can have significant... Read more
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read more
New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
Antibiotic resistance is rising worldwide, threatening the effectiveness of treatments for major infectious diseases, including tuberculosis (TB). Resistance to key TB drugs, such as bedaquiline, is of... Read morePathology
view channel
Intraoperative Tumor Histology to Improve Cancer Surgeries
Surgical removal of cancer remains the first-line treatment for many tumors, but ensuring that all cancerous tissue is removed while preserving healthy tissue is a major challenge. Surgeons currently rely... Read more
Rapid Stool Test Could Help Pinpoint IBD Diagnosis
Inflammatory bowel disease (IBD) is a chronic condition in which the immune system mistakenly attacks the digestive tract, causing persistent gut inflammation. Diagnosis and disease monitoring often depend... Read more
AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read moreTechnology
view channelAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
World Health Expo (WHX) Labs in Dubai (formerly Medlab Middle East), which will be held at Dubai World Trade Centre from 10-13 February, will address the growing global threat of antimicrobial resistance... Read more








